Literature DB >> 33266247

Pathological Functions of LRRK2 in Parkinson's Disease.

Ga Ram Jeong1, Byoung Dae Lee1,2.   

Abstract

Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are common genetic risk factors for both familial and sporadic Parkinson's disease (PD). Pathogenic mutations in LRRK2 have been shown to induce changes in its activity, and abnormal increase in LRRK2 kinase activity is thought to contribute to PD pathology. The precise molecular mechanisms underlying LRRK2-associated PD pathology are far from clear, however the identification of LRRK2 substrates and the elucidation of cellular pathways involved suggest a role of LRRK2 in microtubule dynamics, vesicular trafficking, and synaptic transmission. Moreover, LRRK2 is associated with pathologies of α-synuclein, a major component of Lewy bodies (LBs). Evidence from various cellular and animal models supports a role of LRRK2 in the regulation of aggregation and propagation of α-synuclein. Here, we summarize our current understanding of how pathogenic mutations dysregulate LRRK2 and discuss the possible mechanisms leading to neurodegeneration.

Entities:  

Keywords:  LRRK2; Lewy body; Parkinson’s disease; neurodegeneration; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 33266247      PMCID: PMC7759975          DOI: 10.3390/cells9122565

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  153 in total

1.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau.

Authors:  D N Drechsel; A A Hyman; M H Cobb; M W Kirschner
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

2.  Small GTPase Rab12 regulates transferrin receptor degradation: Implications for a novel membrane trafficking pathway from recycling endosomes to lysosomes.

Authors:  Takahide Matsui; Mitsunori Fukuda
Journal:  Cell Logist       Date:  2011-07-01

3.  α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells.

Authors:  Kazunari Kondo; Saemi Obitsu; Reiko Teshima
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

4.  Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.

Authors:  Petranka Krumova; Lauran Reyniers; Marc Meyer; Evy Lobbestael; Daniela Stauffer; Bertran Gerrits; Lionel Muller; Sjouke Hoving; Klemens Kaupmann; Johannes Voshol; Doriano Fabbro; Andreas Bauer; Giorgio Rovelli; Jean-Marc Taymans; Tewis Bouwmeester; Veerle Baekelandt
Journal:  FASEB J       Date:  2015-04-08       Impact factor: 5.191

5.  Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Authors:  Markos Poulopoulos; Etty Cortes; Jean-Paul G Vonsattel; Stanley Fahn; Cheryl Waters; Lucien J Cote; Carol Moskowitz; Lawrence S Honig; Lorraine N Clark; Karen S Marder; Roy N Alcalay
Journal:  J Mol Neurosci       Date:  2011-12-23       Impact factor: 3.444

6.  LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction.

Authors:  Seongsoo Lee; Hsin-Ping Liu; Wei-Yong Lin; Huifu Guo; Bingwei Lu
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

7.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.

Authors:  Tomas T Ding; Seung-Jae Lee; Jean-Christophe Rochet; Peter T Lansbury
Journal:  Biochemistry       Date:  2002-08-13       Impact factor: 3.162

Review 8.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Authors:  Byoung Dae Lee; Valina L Dawson; Ted M Dawson
Journal:  Trends Pharmacol Sci       Date:  2012-05-09       Impact factor: 14.819

9.  Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.

Authors:  Elena Kozina; Shankar Sadasivan; Yun Jiao; Yuchen Dou; Zhijun Ma; Haiyan Tan; Kiran Kodali; Timothy Shaw; Junmin Peng; Richard J Smeyne
Journal:  Brain       Date:  2018-06-01       Impact factor: 15.255

10.  LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25.

Authors:  Hye Jin Yun; Joohyun Park; Dong Hwan Ho; Heyjung Kim; Cy-Hyun Kim; Hakjin Oh; Inhwa Ga; Hyemyung Seo; Sunghoe Chang; Ilhong Son; Wongi Seol
Journal:  Exp Mol Med       Date:  2013-08-16       Impact factor: 8.718

View more
  10 in total

Review 1.  Long Non-coding RNA HOTAIR in Central Nervous System Disorders: New Insights in Pathogenesis, Diagnosis, and Therapeutic Potential.

Authors:  Jialu Wang; Jiuhan Zhao; Pan Hu; Lianbo Gao; Shen Tian; Zhenwei He
Journal:  Front Mol Neurosci       Date:  2022-06-23       Impact factor: 6.261

Review 2.  Role of SNAREs in Neurodegenerative Diseases.

Authors:  Azzurra Margiotta
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

3.  Variable Effects of PD-Risk Associated SNPs and Variants in Parkinsonism-Associated Genes on Disease Phenotype in a Community-Based Cohort.

Authors:  Katerina Markopoulou; Bruce A Chase; Ashvini P Premkumar; Bernadette Schoneburg; Ninith Kartha; Jun Wei; Hongjie Yu; Alexander Epshteyn; Lisette Garduno; Anna Pham; Rosa Vazquez; Roberta Frigerio; Demetrius Maraganore
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

Review 4.  Atypical Ubiquitination and Parkinson's Disease.

Authors:  Olga Buneeva; Alexei Medvedev
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

Review 5.  Post-transcriptional and Post-translational Modifications of Primary Cilia: How to Fine Tune Your Neuronal Antenna.

Authors:  Cecilia Rocha; Panagiotis Prinos
Journal:  Front Cell Neurosci       Date:  2022-02-28       Impact factor: 5.505

6.  Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression.

Authors:  Alise Zagare; Kyriaki Barmpa; Semra Smajic; Lisa M Smits; Kamil Grzyb; Anne Grünewald; Alexander Skupin; Sarah L Nickels; Jens C Schwamborn
Journal:  Am J Hum Genet       Date:  2022-01-24       Impact factor: 11.025

Review 7.  Monogenetic Forms of Parkinson's Disease - Bridging the Gap Between Genetics and Biomarkers.

Authors:  Lars Tönges; Eun Hae Kwon; Stephan Klebe
Journal:  Front Aging Neurosci       Date:  2022-03-03       Impact factor: 5.750

Review 8.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

9.  The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Authors:  Noémie Cresto; Camille Gardier; Marie-Claude Gaillard; Francesco Gubinelli; Pauline Roost; Daniela Molina; Charlène Josephine; Noëlle Dufour; Gwenaëlle Auregan; Martine Guillermier; Suéva Bernier; Caroline Jan; Pauline Gipchtein; Philippe Hantraye; Marie-Christine Chartier-Harlin; Gilles Bonvento; Nadja Van Camp; Jean-Marc Taymans; Karine Cambon; Géraldine Liot; Alexis-Pierre Bemelmans; Emmanuel Brouillet
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 10.  The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels.

Authors:  Jeswinder Sian-Hulsmann; Peter Riederer
Journal:  Cells       Date:  2021-03-09       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.